Chronic inflammation, cardiometabolic diseases and effects of treatment: Psoriasis as a human model.
Chronic inflammation in humans is associated with accelerated development of cardiometabolic diseases such as myocardial infarction, stroke, and diabetes. Strong evidence from animal models and human interventional trials including CANTOS (The Canakinumab Anti-inflammatory Thrombosis Outcome Study) suggests that targeting residual systemic inflammation in humans may impart a benefit in reducing cardiometabolic diseases. Diseases associated with heightened immune-activation and systemic inflammation including psoriasis, rheumatoid arthritis, systemic lupus erythematosus, and human immunodeficiency virus infection are associated with upwards of two to seven-fold risk of future adverse cardiac events even when adjusted for traditional risk factors. Over the past decade, psoriasis has been utilized as a human model to study inflammatory-induced cardiometabolic dysfunction and to better understand residual risk due to inflammation. The high prevalence and early onset of cardiovascular disease in psoriasis enhances the likelihood of discovering novel pathways in vascular disease progression when followed over time. Furthermore, the United States Food and Drug Administration approved treatments for psoriasis include cytokine inhibitors (anti-tumor necrosis factor, anti-interleukin 17, anti-interleukin 12/23) which while treating the skin disease provide a unique opportunity to characterize how treating the inflammatory pathways may impact atherosclerosis. Herein, we provide a review of chronic inflammation, cardiometabolic disease associations, and treatment effects with a focus on psoriasis as a human model of study.
['Aksentijevich|Milena|M|', 'Lateef|Sundus S|SS|', 'Anzenberg|Paula|P|', 'Dey|Amit K|AK|', 'Mehta|Nehal N|NN|']
D000818:Animals D000893:Anti-Inflammatory Agents D000083202:Cardiometabolic Risk Factors D002318:Cardiovascular Diseases D002908:Chronic Disease D016207:Cytokines D006801:Humans D007249:Inflammation D018836:Inflammation Mediators D024821:Metabolic Syndrome D011379:Prognosis D011565:Psoriasis D018570:Risk Assessment D015398:Signal Transduction
Inflammation Cardiometabolic disease Psoriasis Adipose dysfunction Immune activation Lipoprotein dysfunction